Adjuvant radiotherapy given to men within 18 weeks of a diagnosis of T3 prostate cancer after radical prostatectomy benefit from increased survival, increased metastasis free survival, a 7 year delay to PSA failure and freedom from long term hormone thera.
Salvage radiotherapy for biochemical failure after radical prostatectomy works best when the preradiotherapy PSA <0.6 ng/mL, long PSADT >10 months, positive margins, no seminal vesicle invasion and Gleason 4-7.
Men with Gleason 5-6 prostate cancer followed for 24 years and treated conservatively have a very low risk of dying from prostate cancer whereas men with Gleason 7-10 are likely to die from prostate cancer.
Immediate hormones in men with positive lymph nodes after radical prostatectomy is associated with a progression free survival benefit of 14 years versus 2.4 years if just watched and better overall and prostate cancer specific survival at 12 years.
Zoledronic acid 4 mg infusion every 3 weeks in men with bone metastases in hormone resistant prostate cancer and normal kidney function have 11% fewer skeletal complications including fewer fractures, a longer time to any skeletal problem and less pain.
Benign prostatic hypertrophy (BPH) – news and research
Combination medical therapy with alpha blocker plus finasteride reduces clinical progression of BPH more than either drug alone, and combination or finasteride alone reduces the risk of acute urinary retention or needing surgery (MTOPS).
Photoselective vaporization of the prostate using 80-W or 120-W laser has equivalent functional outcomes but less bleeding, shorter catheterization times and shorter hospital stay than traditional TURP.